110 related articles for article (PubMed ID: 37309095)
21. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression.
Witzens-Harig M; Giaisi M; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2016 Jan; 138(2):507-14. PubMed ID: 26260669
[TBL] [Abstract][Full Text] [Related]
22. PROTACs are effective in addressing the platelet toxicity associated with BCL-X
Zhang P; Zhang X; Liu X; Khan S; Zhou D; Zheng G
Explor Target Antitumor Ther; 2020; 1(4):259-272. PubMed ID: 34296214
[TBL] [Abstract][Full Text] [Related]
23. Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence.
Nor Hisam NS; Ugusman A; Rajab NF; Ahmad MF; Fenech M; Liew SL; Mohamad Anuar NN
Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575429
[TBL] [Abstract][Full Text] [Related]
24. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
Dieudonné FX; Marion A; Marie PJ; Modrowski D
J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
[TBL] [Abstract][Full Text] [Related]
25. Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma multiforme through de-repression of Bcl-xL translation.
Liwak U; Jordan LE; Von-Holt SD; Singh P; Hanson JE; Lorimer IA; Roncaroli F; Holcik M
Oncotarget; 2013 Sep; 4(9):1365-72. PubMed ID: 23965755
[TBL] [Abstract][Full Text] [Related]
26. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
[TBL] [Abstract][Full Text] [Related]
27. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL.
Haselager M; Thijssen R; West C; Young L; Van Kampen R; Willmore E; Mackay S; Kater A; Eldering E
Cell Death Differ; 2021 May; 28(5):1658-1668. PubMed ID: 33495554
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-221 Upregulates the Expression of P-gp and Bcl-2 by Activating the Stat3 Pathway to Promote Doxorubicin Resistance in Osteosarcoma Cells.
Liu Y; Liu X; Yang S
Biol Pharm Bull; 2021 Jun; 44(6):861-868. PubMed ID: 33828027
[TBL] [Abstract][Full Text] [Related]
29. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance.
Kim J; Shim MK; Yang S; Moon Y; Song S; Choi J; Kim J; Kim K
J Control Release; 2021 Feb; 330():920-932. PubMed ID: 33152391
[TBL] [Abstract][Full Text] [Related]
30. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
31. Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2.
Zhang C; Zhao Y; Zeng B
Cancer Biomark; 2012; 12(4):155-67. PubMed ID: 23568006
[TBL] [Abstract][Full Text] [Related]
32. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x
Balachander SB; Criscione SW; Byth KF; Cidado J; Adam A; Lewis P; Macintyre T; Wen S; Lawson D; Burke K; Lubinski T; Tyner JW; Kurtz SE; McWeeney SK; Varnes J; Diebold RB; Gero T; Ioannidis S; Hennessy EJ; McCoull W; Saeh JC; Tabatabai A; Tavana O; Su N; Schuller A; Garnett MJ; Jaaks P; Coker EA; Gregory GP; Newbold A; Johnstone RW; Gangl E; Wild M; Zinda M; Secrist JP; Davies BR; Fawell SE; Gibbons FD
Clin Cancer Res; 2020 Dec; 26(24):6535-6549. PubMed ID: 32988967
[TBL] [Abstract][Full Text] [Related]
33. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.
Al-Harbi S; Choudhary GS; Ebron JS; Hill BT; Vivekanathan N; Ting AH; Radivoyevitch T; Smith MR; Shukla GC; Almasan A
Mol Cancer; 2015 Nov; 14():185. PubMed ID: 26537004
[TBL] [Abstract][Full Text] [Related]
34. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.
Zhao H; Guo W; Peng C; Ji T; Lu X
Mol Biol Rep; 2010 Jun; 37(5):2509-15. PubMed ID: 19701692
[TBL] [Abstract][Full Text] [Related]
36. Pyrrolidine dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to doxorubicin by inducing paraptosis.
Park SS; Lee DM; Lim JH; Lee D; Park SJ; Kim HM; Sohn S; Yoon G; Eom YW; Jeong SY; Choi EK; Choi KS
Carcinogenesis; 2018 Mar; 39(3):458-470. PubMed ID: 29329420
[TBL] [Abstract][Full Text] [Related]
37. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
38. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1.
Wang MY; Chen PS; Prakash E; Hsu HC; Huang HY; Lin MT; Chang KJ; Kuo ML
Cancer Res; 2009 Apr; 69(8):3482-91. PubMed ID: 19351859
[TBL] [Abstract][Full Text] [Related]
39. Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X
Kehr S; Haydn T; Bierbrauer A; Irmer B; Vogler M; Fulda S
Cancer Lett; 2020 Jul; 482():19-32. PubMed ID: 32145345
[TBL] [Abstract][Full Text] [Related]
40. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
